Compare IBP & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBP | RYTM |
|---|---|---|
| Founded | 1977 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.8B |
| IPO Year | 2014 | 2017 |
| Metric | IBP | RYTM |
|---|---|---|
| Price | $206.09 | $104.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $266.14 | $131.14 |
| AVG Volume (30 Days) | 270.7K | ★ 432.7K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | 6.70 | ★ 28.34 |
| EPS | ★ 3.71 | N/A |
| Revenue | ★ $2,970,800,000.00 | N/A |
| Revenue This Year | $1.96 | $55.34 |
| Revenue Next Year | $4.32 | $86.06 |
| P/E Ratio | $56.75 | ★ N/A |
| Revenue Growth | ★ 1.00 | N/A |
| 52 Week Low | $193.11 | $74.50 |
| 52 Week High | $349.00 | $122.20 |
| Indicator | IBP | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 28.05 | 38.90 |
| Support Level | $195.46 | $99.14 |
| Resistance Level | $229.34 | $113.04 |
| Average True Range (ATR) | 9.12 | 4.02 |
| MACD | -4.84 | -1.21 |
| Stochastic Oscillator | 0.58 | 19.49 |
Installed Building Products Inc is an insulation installer serving the residential new construction market and are also a diversified installer of complementary building products, including waterproofing, fire-stopping and fireproofing, garage doors, rain gutters, window blinds, shower doors, closet shelving, mirrors and other products throughout the United States. The company installs fiberglass insulation, spray foam insulation, and cellulose insulation. The company has three operating segments consisting of Installation, Manufacturing and Distribution operations. Majority of revenue is derived from Installation segment.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.